Clinical Trial Update: Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

View source ↗

Summary

The study evaluating Mylotarg (gemtuzumab ozogamicin) in usual care for acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Acute Myeloid Leukemia | Status: COMPLETED